Perhaps Bioceuticals to be recognised in this coming quarter - I too was expecting the opposite though, Bioceuticals to be recognised this quarter and not PuMate, although that is comforting to see revenue already coming in from China avenues.
Slow progress, but the hard work in signing contracts is done, the remaining hard work now needs to go to fulfill them over the next 3-6 months and get that revenue on the bottom line.
Ann: Appendix 4C Quarterly Activity and Cashflow Reports, page-15
Add CCO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.284M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $15.15K | 2.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 13187903 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 6932800 | 8 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 7843 | ||
| Last updated 10.26am 29/05/2024 ? | |||||
| CCO (ASX) Chart |